Barcelona biomedical SME specializing in chronic disease screening, diabetes complications, and liver fibrosis detection across pan-European clinical consortia.
GENESIS BIOMED is a Barcelona-based biomedical SME that contributes specialist clinical research expertise to large, pan-European health research consortia. Their work centers on chronic disease — specifically the mechanisms and early detection of complications linked to type 2 diabetes (retinopathy, cognitive decline, neurodegeneration) and the population-level screening of liver fibrosis across different European healthcare systems. Rather than running their own research programs, they bring targeted domain knowledge — likely clinical data access, patient cohort management, disease phenotyping, or health economics analysis — to established multi-institutional projects. As a private company competing for RIA funding alongside universities and research institutes, they occupy the niche of a clinical-bridge partner between academic research and real-world disease management.
In RECOGNISED (2020–2024), GENESIS BIOMED contributed to unraveling shared pathways between diabetic retinopathy, cognitive impairment, and Alzheimer disease in type 2 diabetes patients.
In LiverScreen (2020–2025), they participated in a multi-country European study on screening methodology and risk stratification for liver fibrosis using transient elastography (TE) technology.
Both RECOGNISED and LiverScreen require patient phenotyping, biomarker validation, and stratification of high-risk subpopulations — consistent expertise threads across both projects.
LiverScreen explicitly includes cost-effectiveness analysis and implementation strategy as outputs, suggesting GENESIS BIOMED contributes to or leads the translational and health-system-facing dimensions of that project.
Both projects began in 2020, so the keyword split does not reflect a true temporal career arc — it reflects two concurrent but distinct specializations rather than a shift over time. That said, RECOGNISED anchors their work in disease mechanism research (retinal-cognitive pathways, neurodegeneration, clinical phenotypes), while LiverScreen points toward a more translational orientation: screening methodology, TE technology validation, risk factor stratification, and cost-effectiveness. If a direction is emerging, it is toward population-facing, health-system-integrated research where clinical expertise connects to real-world implementation — a meaningful step beyond pure mechanism science.
GENESIS BIOMED appears to be broadening from disease-mechanism research toward translational work — population screening, risk stratification, and health-system implementation — which positions them well for future consortia focused on chronic disease prevention and early detection at scale.
GENESIS BIOMED has never led an H2020 project, always joining as a participant — a consistent pattern of specialist contribution within larger, coordinator-led consortia. Despite only two projects, they have engaged with 46 unique partners across 13 countries, which reflects involvement in large, geographically distributed research networks rather than tight bilateral partnerships. This profile suits organizations that offer a defined, in-demand capability (clinical access, a specific methodology, or domain knowledge) that consortium builders want to include but not replicate internally.
With 46 unique consortium partners across 13 countries from just two projects, GENESIS BIOMED is embedded in broad pan-European research networks despite their small size. Their Barcelona location positions them as a southern European clinical access point within consortia that are typically coordinated from Northern or Western Europe.
GENESIS BIOMED is unusual as a small private company securing competitive EU RIA funding — most private-sector participants at this scale are contract research organizations or health IT firms, making their biomedical focus distinctive. Their dual coverage of neurodegeneration-linked diabetes complications and liver fibrosis screening gives them cross-disease chronic condition expertise that is rare in a single SME. For consortium builders targeting the growing European chronic disease burden, they offer a Spanish patient population entry point combined with health economics analytical capacity — a combination that strengthens both the clinical and implementation arms of a project.
